168471-19-0

Basic information

• Product Name: 2-[(R)-1-{(S)-2-[(Indole-1-carbonyl)-amino]-4-methyl-pentanoylamino}-2-(1-methyl-1H-indol-3-yl)-ethyl]-5-methyl-oxazole-4-carboxylic acid benzyl ester
• Synonyms: 2-[(R)-1-{(S)-2-[(Indole-1-carbonyl)-amino]-4-methyl-pentanoylamino}-2-(1-methyl-1H-indol-3-yl)-ethyl]-5-methyl-oxazole-4-carboxylic acid benzyl ester
• CAS NO: 168471-19-0
• Molecular Weight: 645.758
• Mol File: 168471-19-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-[(R)-1-{(S)-2-[(Indole-1-carbonyl)-amino]-4-methyl-pentanoylamino}-2-(1-methyl-1H-indol-3-yl)-ethyl]-5-methyl-oxazole-4-carboxylic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(R)-1-{(S)-2-[(Indole-1-carbonyl)-amino]-4-methyl-pentanoylamino}-2-(1-methyl-1H-indol-3-yl)-ethyl]-5-methyl-oxazole-4-carboxylic acid benzyl ester(168471-19-0)
• EPA Substance Registry System: 2-[(R)-1-{(S)-2-[(Indole-1-carbonyl)-amino]-4-methyl-pentanoylamino}-2-(1-methyl-1H-indol-3-yl)-ethyl]-5-methyl-oxazole-4-carboxylic acid benzyl ester(168471-19-0)

Safety Data

• Hazardous Substances Data: 168471-19-0(Hazardous Substances Data)

Upstream product

• 13884-13-4 indole-1-carboxylic acid 
• 168471-18-9 (S)-2-[(Indole-1-carbonyl)-amino]-4-methyl-pentanoic acid benzyl ester 
• 1738-69-8 L-Leucine benzyl ester 
• 168471-17-8 N-(indol-1-ylcarbonyl)leucine 
• 168470-88-0 2-[(R)-1-Amino-2-(1-methyl-1H-indol-3-yl)-ethyl]-5-methyl-oxazole-4-carboxylic acid benzyl ester 

Relevant articles and documents

Azole endothelin antagonists. 2. Structure-activity studies

Structure-activity studies have been performed in an attempt to improve the potency of a novel series of azole-based endothelin-A (ET(A)) selective antagonists. Modifications of the hydrophobic group on the terminal urea produced substantial effects on receptor affinity; in particular, the choice of cyclohexyl- or arylureas led to substantial improvements in activity. Conformational restriction of these groups provides an additional benefit. N- Methylation of the indole moiety which is part of the heterocyclic dipeptide surrogate also improves potency. The effects of these two modifications appear to be synergistic, with the best of the resultant doubly modified analogs (e.g. 14q, 15y, and 15ff) exhibiting an 80-200-fold improvement over the original leads.